Intelligencia

Greek-owned Intelligencia, headquartered in New York, is an AI/ML software platform that caters to pharmaceutical and biotechnology companies. The company uses proprietary and curated data with ML algorithms to quantify and ultimately reduce the risk of clinical development and speed up the drug development process. It also uses AI to predict the likelihood of clinical trial success and provides input on how to improve or other areas of research that can be targeted. 

The company offers four solutions that aim to reduce risks in drug development, improve productivity and costs across preclinical and clinical development, and boost business strategies. These solutions are 1) Portfolio Optimizer - to assess the probability of technical and regulatory success (PTRS) of drug pipelines; 2) Asset Optimizer - to run predictive analytics and sensitivity analyses on hundreds of parameters to design trials; 3) Business Development and Licensing (BD&L) navigation - to identify and prioritize external assets for specific areas of interest; and 4) Breakthrough Science - to give access to a library of emerging technological and scientific data. 

Founded in 2017, the company raised USD 12 million in Series A funding in August 2021 to expand its research and development (R&D) and sales teams and broadening its product offerings and customer base.